References
- Molimard M, Bamberger M, Vray M. Value of post-registration studies for reimbursement renewal. Therapie. 2009; 64:203–213.
- Le Jeunne C, Woronoff-Lemsi MC, David N, de Sahb R. Relative added value: What are the tools to evaluate it? Therapie. 2008;63:107–111.
- Liou C-W, Yeh T-C, Chen I-C, Huang C-H, Hung Y-J, Hsu K-L, . Efficacy and safety of valseartan in hypertensive Taiwanese patients: Post-marketing surveillence study. Blood Press. 2011; 20 Suppl 2:13–21.
- Devi P, Xavier D, Sigamani A, Pandey S, Thomas T, Murthy S, . Effect of fixed dose combinations of metoprolol and amlodipine in hypertension: MARS – A randomized controlled trial. Blood Press. 2011;20 Suppl 2:5–12.
- Girerd X, Rosenbaum D, Aoun J on behalf of ACTUAL Study Investigators. Efficacy and safety of early versus late titration of fixed-dose irbesartan/hydrochlorothiazide: ACTUAL study. Blood Press. 2011;20 Suppl 2:22–29.
- Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded End-point (PROBE) study. A novel design for intervention trials. Blood Press. 1992;1:113–119.
- Wieringa NF, Rein Vos R, Van Der Werf GT, Van Der Veen WJ, De Graeff PA. Co-morbidity of ‘clinical trial’ versus ‘real-world’ patients using cardiovascular drugs. Pharmacoepidemiol Drug Safety. 2000;9:569–579.
- Parati G, Staessen JA. Hypertension drug trials based on ambulatory blood pressure monitoring: When is a double-blind controlled design needed? J Hypertens. 2003;21:1237–1239.
- Massol J, Puech A, Boissel JP; Participants in Round Table No 7, Giens XXII. How to anticipate the assessment of the public health benefit of new medicines? Therapie. 2007; 62:427–435.